December 6, 2021. We strongly support the “D” grade reaffirmation of the 2016 recommendation against screening for COPD in asymptomatic adults. There is simply not sufficient evidence that screening for COPD in asymptomatic adults (or treatments for asymptomatic adults) reduce morbidity or mortality or improve health-related quality of life.
Read More »Tag: COPD
NCHR’s Testimony to FDA Regarding Proposed Labeling for TRELEGY ELLIPTA
August 31, 2020: We share the concerns of the FDA scientists that trends shown by the data do not support the claim that TRELEGY improves all-cause mortality.
Read More »